The UK and US have signed a important trade agreement that will ensure no tariffs on UK pharmaceutical shipments going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to raise expenditure on pharmaceuticals through the public health system. This commitment secures that tariffs on these key products will remain at zero for a timeframe of three years.
This agreement comes after previous threats to dramatically increase duties on branded pharmaceutical imports, with increases mentioned up to double the cost.
"This arrangement between the United Kingdom reinforces the worldwide climate for new treatments and introduces long-overdue fairness to transatlantic drug exports," a statement declared.
Commercial Importance
Drugs represent one of the the United Kingdom's largest goods shipped to the America, which is clearly the primary destination for major companies like GSK and AstraZeneca.
Trade data reveal that in the one-year period prior to the third quarter, the UK sold pharmaceutical products valued at over eleven billion pounds to the US. This value made up 17.4% of all goods exports in that span.
"This deal safeguards work, increases funding and sets the stage for the UK to establish itself as a international leader for life sciences," a government official commented.
Detailed UK Commitments
The deal entails several key commitments from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to double total health service expenditure on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be limited at fifteen percent. Previously, repayments topped 20%.
Recent Tensions
The pact takes place against a ongoing tension between the pharmaceutical industry and the ministers over medicine costs and approval rates.
This friction were heightened by arguments that US consumers were charged significantly more for the same drugs than consumers in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure stated that the NHS had to spend more on treatments, noting that its spending on drugs had declined as a percentage of its overall budget over the previous ten-year period.
